Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Jo-Ann Johnson1, Kim MacDonald2, Gwen Clarke3

  • 1Calgary (Alb.).

Journal of Obstetrics and Gynaecology Canada : JOGC = Journal D'Obstetrique Et Gynecologie Du Canada : JOGC
|April 30, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Navigating the Grey Zone: A Mixed-Methods Study to Evaluate a Decision Support Tool in the SOGC Late Preterm Antenatal Corticosteroids Guideline.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC·2026
Same author

Survey of national and regional rare donor programmes regarding Immunoglobulin A deficiency.

Vox sanguinis·2026
Same author

Expanding First-Trimester Preterm Preeclampsia Screening With Placental Growth Factor Testing.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC·2026
Same author

Hold on to your units: Quality of red cell concentrates is only affected after multiple transient warming events.

Transfusion·2026
Same author

Clinical significance of anti-M in pregnancy and self-reported ancestry: The BEST collaborative study.

Transfusion·2026
Same author

Antenatal Rh Immune Globulin Dose, Timing, and Indications After Selected Procedures and Complications: A Scoping Review.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC·2026

Non-invasive fetal RHD genotyping using cell-free DNA (cfDNA) in maternal plasma allows targeted anti-D prophylaxis for Rh-negative women. This approach optimizes care for Rh-negative pregnancies by identifying fetuses with the D antigen.

Area of Science:

  • Maternal-fetal medicine
  • Genetics
  • Immunology

Context:

  • Current standard of care for Rh-negative pregnancies involves predicting fetal D antigen status.
  • Non-invasive prenatal testing (NIPT) using cell-free DNA (cfDNA) is becoming a global standard.
  • Canada's existing routine antenatal anti-D prophylaxis program.

Purpose:

  • To review the current national landscape of fetal RHD genotyping via cfDNA.
  • To evaluate the benefits and challenges of targeted RHD genotyping and prophylaxis.
  • To provide recommendations for optimizing Rh-negative pregnancy care in Canada.

Summary:

  • Predicting fetal D antigen status non-invasively using maternal plasma cfDNA is the optimal management for Rh-negative pregnancies.
  • Targeted anti-D prophylaxis for Rh-positive fetuses improves maternal and infant outcomes.

Related Experiment Videos

  • Canadian guidelines are being updated based on national consensus regarding fetal RHD genotyping.

    • Impact:

    • Enhances optimal care for Rh-negative pregnant individuals.
    • Reduces unnecessary anti-D immunoglobulin administration.
    • Aligns Canadian practices with international standards for Rh disease prevention.